Edward M Schaeffer

List of Publications by Year
in descending order

191 papers	8,326 citations	53794 45 h-index	53230 85 g-index
193 all docs	193 docs citations	193 times ranked	10271 citing authors

#	Article	IF	Citations
1	Real-world use of MRI for risk stratification prior to prostate biopsy. Prostate Cancer and Prostatic Diseases, 2023, 26, 353-359.	3.9	8
2	High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer and Prostatic Diseases, 2023, 26, 105-112.	3.9	2
3	Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. European Urology, 2022, 81, 325-330.	1.9	7
4	A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 659-665.	3.9	9
5	Reporting of Racial Health Disparities Research: Are We Making Progress?. Journal of Clinical Oncology, 2022, 40, 8-11.	1.6	11
6	Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. European Urology Open Science, 2022, 37, 53-63.	0.4	26
7	Association of B7â€H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer, 2022, 128, 2269-2280.	4.1	16
8	Grade Migration of Prostate Cancer in the United States During the Last Decade. Journal of the National Cancer Institute, 2022, 114, 1012-1019.	6.3	13
9	Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. European Urology, 2022, 82, 341-351.	1.9	32
10	MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications, 2022, 13, 2559.	12.8	56
11	Abstract 462: Using attention-based deep multiple instance learning to identify key genetic alterations in prostate cancer from whole slide images. Cancer Research, 2022, 82, 462-462.	0.9	0
12	Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. European Urology Oncology, 2021, 4, 955-962.	5.4	14
13	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology, 2021, 79, 374-383.	1.9	93
14	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Modern Pathology, 2021, 34, 1185-1193.	5.5	61
15	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature Communications, 2021, 12, 935.	12.8	56
16	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
17	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncology, The, 2021, 22, 402-410.	10.7	79
18	Local anaesthetic techniques for performing transperineal prostate biopsy. Nature Reviews Urology, 2021, 18, 315-317.	3.8	5

#	Article	IF	Citations
19	Cause of death during prostate cancer survivorship: A contemporary, US populationâ€“based analysis. Cancer, 2021, 127, 2895-2904.	4.1	24
20	A PRC2-independent function for EZH2 in regulating rRNA 2â€²-O methylation and IRES-dependent translation. Nature Cell Biology, 2021, 23, 341-354.	10.3	54
21	TNF-alpha immunosuppressive use and future malignancy risk.. Journal of Clinical Oncology, 2021, 39, 10558-10558.	1.6	1
22	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Communications Biology, 2021, 4, 670.	4.4	50
23	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology, 2021, 79, 717-721.	1.9	13
24	Performance of prostate health index and PSA density in a diverse biopsyâ€naÃ¯ve cohort with mpMRI for detecting significant prostate cancer. BJUI Compass, 2021, 2, 370-376.	1.3	6
25	It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?. Cancer, 2021, 127, 3354-3360.	4.1	5
26	Abstract 2546: Predictive value of prostate health index (PHI) in multi-parametric MRI in an ethnically diverse cohort. , 2021, , .		0
27	Influence of Department Leadership on Scholarly Productivity and Research Funding in Academic Urology. Urology, 2021, 154, 136-140.	1.0	0
28	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.4	2
29	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. JAMA Network Open, 2021, 4, e2139769.	5.9	16
30	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer and Prostatic Diseases, 2020, 23, 179-183.	3.9	12
31	Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines. Urology, 2020, 135, 1-3.	1.0	5
32	The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years. Urology Practice, 2020, 7, 145-151.	0.5	11
33	Risk Factors for Infection after Prostate Biopsy in the United States. Urology, 2020, 138, 113-118.	1.0	11
34	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	3.0	2
35	Neuroendocrine differentiation in usualâ€type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 2020, 80, 1012-1023.	2.3	22
36	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. JAMA Oncology, 2020, 6, 1793.	7.1	10

#	Article	IF	Citations
37	Racial Differences in Genomic Profiling of Prostate Cancer. New England Journal of Medicine, 2020, 383, 1083-1085.	27.0	87
38	Changes in prostateâ€specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men. Cancer, 2020, 126, 3229-3236.	4.1	9
39	Association between inflammatory bowel disease and prostate cancer: A largeâ€scale, prospective, populationâ€based study. International Journal of Cancer, 2020, 147, 2735-2742.	5.1	28
40	A novel immunocompetent model of metastatic prostate cancerâ€induced bone pain. Prostate, 2020, 80, 782-794.	2.3	6
41	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology, 2020, 78, 327-332.	1.9	18
42	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncology, 2020, 6, 735.	7.1	58
43	Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes. Journal of Clinical Medicine, 2020, 9, 1973.	2.4	10
44	CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. Clinical Cancer Research, 2020, 26, 2595-2602.	7.0	16
45	Association between surgical approach and survival following resection of abdominopelvic malignancies. Journal of Surgical Oncology, 2020, 121, 620-629.	1.7	2
46	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases, 2020, 23, 646-653.	3.9	17
47	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. Clinical Cancer Research, 2020, 26, 3182-3192.	7.0	64
48	Surgical versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. Journal of Urology, 2020, 203, 933-939.	0.4	19
49	Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2020, 38, 24-24.	1.6	5
50	Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests.. Journal of Clinical Oncology, 2020, 38, 348-348.	1.6	1
51	Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.. Journal of Clinical Oncology, 2020, 38, 337-337.	1.6	0
52	Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, 295-295.	1.6	0
53	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2020, 38, e17517-e17517.	1.6	0
54	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clinical Cancer Research, 2019, 25, 5608-5622.	7.0	17

#	Article	IF	Citations
55	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. European Urology Oncology, 2019, 2, 589-596.	5.4	19
56	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications, 2019, 10, 4358.	12.8	109
57	Definitive and sustained increase in prostate cancer metastases in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 988-990.	1.6	7
58	Association of Black Race With Prostate Cancerâ€"Specific and Other-Cause Mortality. JAMA Oncology, 2019, 5, 975.	7.1	288
59	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. International Journal of Cancer, 2019, 145, 3453-3461.	5.1	18
60	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 309-320.	3.8	42
61	Prostate cancer in sexual minorities and the influence of HIV status. Nature Reviews Urology, 2019, 16, 404-421.	3.8	17
62	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. Human Pathology, 2019, 87, 95-102.	2.0	34
63	SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy. Prostate Cancer and Prostatic Diseases, 2019, 22, 552-559.	3.9	13
64	The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods. Urology, 2019, 129, 153-159.	1.0	18
65	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment NaÃ¯ve Primary Prostate Cancer. Clinical Cancer Research, 2019, 25, 6721-6730.	7.0	74
66	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European Urology Oncology, 2019, 2, 405-412.	5.4	14
67	A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. BMC Urology, 2019, 19, 121.	1.4	16
68	Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	9
69	Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment. World Journal of Urology, 2019, 37, 2623-2629.	2.2	21
70	Outcomes of very highâ€risk prostate cancer after radical prostatectomy: Validation study from 3 centers. Cancer, 2019, 125, 391-397.	4.1	37
71	National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 353.e1-353.e8.	1.6	2
72	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 292-302.	3.9	10

#	Article	IF	Citations
73	The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute, 2019, 111, 301-310.	6.3	142
74	Inflammatory Bowel Disease and the Risk of Prostate Cancer. European Urology, 2019, 75, 846-852.	1.9	47
75	African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. Journal of Urology, 2019, 202, 247-255.	0.4	19
76	A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host. Oncotarget, 2019, 10, 6845-6854.	1.8	11
77	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
78	Risk factors for postprostate biopsy infection.. Journal of Clinical Oncology, 2019, 37, 103-103.	1.6	0
79	Percent genome alteration and outcomes after radical prostatectomy in African American men.. Journal of Clinical Oncology, 2019, 37, 24-24.	1.6	0
80	SPINK1 expression and outcomes postprostatectomy in race-specific cohorts.. Journal of Clinical Oncology, 2019, 37, 23-23.	1.6	0
81	Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.. Journal of Clinical Oncology, 2019, 37, 55-55.	1.6	0
82	Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).. Journal of Clinical Oncology, 2019, 37, TPS333-TPS333.	1.6	0
83	National society-supplied patient materials on prostate cancer screening for the general public: A readability analysis.. Journal of Clinical Oncology, 2019, 37, e23188-e23188.	1.6	0
84	Clinical and Genomic Characterization of Lowâ€"Prostate-specific Antigen, High-grade Prostate Cancer. European Urology, 2018, 74, 146-154.	1.9	72
85	Gender Representation in Urologic Subspecialties. Urology, 2018, 114, 66-70.	1.0	32
86	Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. Journal of Urology, 2018, 199, 1510-1517.	0.4	31
87	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology, 2018, 73, 168-175.	1.9	53
88	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology, 2018, 73, 524-532.	1.9	60
89	The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004â€"2013). Urologic Oncology: Seminars and Original Investigations, 2018, 36, 91.e1-91.e6.	1.6	32
90	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. European Urology, 2018, 74, 107-114.	1.9	54

#	Article	IF	Citations
91	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 2018, 199, 126-132.	0.4	86
92	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	14
93	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	1.6	155
94	The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. Journal of Urology, 2018, 200, 1048-1055.	0.4	2
95	â€œReal-worldâ€•Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. European Urology, 2018, 74, 708-709.	1.9	0
96	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clinical Cancer Research, 2018, 24, 3908-3916.	7.0	24
97	Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Modern Pathology, 2018, 31, 1539-1552.	5.5	70
98	Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1376-1383.	2.5	9
99	Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk. European Urology, 2018, 74, 453-454.	1.9	1
100	Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass.. Journal of Clinical Oncology, 2018, 36, 2-2.	1.6	1
101	The influence of decision aids on prostate cancer screening preferences: A randomized survey study.. Journal of Clinical Oncology, 2018, 36, 5085-5085.	1.6	0
102	Inflammatory bowel disease and the risk of prostate cancer.. Journal of Clinical Oncology, 2018, 36, e17052-e17052.	1.6	0
103	The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. European Urology, 2017, 71, 174-180.	1.9	75
104	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. Journal of Urology, 2017, 197, 1245-1250.	0.4	16
105	Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer, 2017, 123, 2240-2247.	4.1	2
106	The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology, 2017, 14, 215-229.	3.8	89
107	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	7.1	219
108	TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. Cancer Research, 2017, 77, 3181-3193.	0.9	102

#	Article	IF	Citations
109	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clinical Cancer Research, 2017, 23, 4693-4703.	7.0	62
110	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	6.4	99
111	Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. Bladder Cancer, 2017, 3, 45-49.	0.4	17
112	Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. Journal of Molecular Diagnostics, 2017, 19, 475-484.	2.8	16
113	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	7.0	87
114	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. European Urology, 2017, 71, 697-700.	1.9	65
115	Complications After Systematic, Random, and Image-guided Prostate Biopsy. European Urology, 2017, 71, 353-365.	1.9	353
116	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. Journal of Urology, 2017, 197, 122-128.	0.4	33
117	Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database. Journal of Urology, 2017, 197, 627-631.	0.4	35
118	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	3.8	210
119	Progress in Prognosis and Prediction for Men with Prostate Cancer. European Urology, 2017, 72, 32-33.	1.9	1
120	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. Oncotarget, 2017, 8, 104182-104192.	1.8	20
121	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget, 2017, 8, 50804-50813.	1.8	29
122	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. Journal of Clinical Oncology, 2017, 35, 1982-1990.	1.6	76
123	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017, 35, 1991-1998.	1.6	176
124	Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk.. Journal of Clinical Oncology, 2017, 35, 5000-5000.	1.6	4
125	Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5020-5020.	1.6	2
126	Neoadjuvant randomized trial of degarelix (Deg) Â± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 5077-5077.	1.6	12

#	Article	IF	Citations
127	Race, demographics, and socioeconomics as they relate to newly diagnosed metastatic prostate cancer in the United States.. Journal of Clinical Oncology, 2017, 35, 195-195.	1.6	1
128	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 35, 3-3.	1.6	2
129	Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues.. Journal of Clinical Oncology, 2017, 35, 38-38.	1.6	2
130	The impact of race on perceptions of anxiety after radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, e538-e538.	1.6	0
131	Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease.. Journal of Clinical Oncology, 2017, 35, 133-133.	1.6	1
132	Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model.. Journal of Clinical Oncology, 2017, 35, 142-142.	1.6	0
133	Luminal and basal subtyping of prostate cancer.. Journal of Clinical Oncology, 2017, 2017, 3-3.	1.6	0
134	Temporal trends and factors associated with overuse of neoadjuvant androgen deprivation therapy in low and very low risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 28-28.	1.6	0
135	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	3.8	26
136	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	4.9	544
137	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. Journal of Urology, 2016, 196, 1436-1444.	0.4	38
138	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.3	0
139	The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. Urology, 2016, 97, 8-12.	1.0	15
140	Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports, 2016, 9, 51-54.	0.3	0
141	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	10.7	182
142	Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research, 2016, 76, 4948-4958.	0.9	147
143	Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer. Urology Case Reports, 2016, 7, 64-66.	0.3	2
144	Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. Urology, 2016, 90, 136-140.	1.0	18

#	Article	IF	Citations
145	Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. European Urology, 2016, 70, 14-17.	1.9	79
146	The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clinical Cancer Research, 2016, 22, 1777-1786.	7.0	42
147	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 496-504.	1.9	23
148	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. European Urology, 2016, 69, 576-581.	1.9	42
149	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 157-165.	1.9	206
150	Development and validation of genomic signature to predict ADT treatment failure.. Journal of Clinical Oncology, 2016, 34, 5018-5018.	1.6	1
151	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.. Journal of Clinical Oncology, 2016, 34, 303-303.	1.6	2
152	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS ONE, 2016, 11, e0146189.	2.5	13
153	Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.. Journal of Clinical Oncology, 2016, 34, 106-106.	1.6	0
154	Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk.. Journal of Clinical Oncology, 2016, 34, 12-12.	1.6	0
155	Effect of local therapy on the systemic anti-tumor response in prostate cancer.. Journal of Clinical Oncology, 2016, 34, 243-243.	1.6	0
156	Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 299-299.	1.6	0
157	Contemporary treatment patterns and short-term outcomes in men with very high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	0
158	The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.. Journal of Clinical Oncology, 2016, 34, 256-256.	1.6	1
159	Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues.. Journal of Clinical Oncology, 2016, 34, 5055-5055.	1.6	0
160	Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients.. Journal of Clinical Oncology, 2016, 34, 5056-5056.	1.6	0
161	Bacterial Prostatitis Enhances 2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine (PhIP)â€"Induced Cancer at Multiple Sites. Cancer Prevention Research, 2015, 8, 683-692.	1.5	17
162	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. Urology, 2015, 86, 942-946.	1.0	10

#	Article	IF	Citations
163	Fluoroquinolone Resistance in the Rectal Carriage of Men in an Active Surveillance Cohort: Longitudinal Analysis. Journal of Urology, 2015, 193, 552-556.	0.4	29
164	Iatrogenic Extraprostatic Extension of Prostate Cancer From a Needle Biopsy. Urology Case Reports, 2015, 3, 56-58.	0.3	1
165	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology, 2015, 68, 555-567.	1.9	125
166	Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 2789-2796.	1.6	127
167	Re: Steven Joniau, Alberto Briganti, Paolo Gontero, et al. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. Eur Urol 2015;67:157â€"64. European Urology, 2015, 68, e11-e12.	1.9	1
168	HES6 promotes prostate cancer aggressiveness independently of Notch signalling. Journal of Cellular and Molecular Medicine, 2015, 19, 1624-1636.	3.6	18
169	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research, 2015, 21, 5619-5629.	7.0	56
170	Reclassification Rates Are Higher Among African American Men Than Caucasians on Active Surveillance. Urology, 2015, 85, 155-160.	1.0	64
171	Magnetic Resonanceâ€"invisible Versus Magnetic Resonanceâ€"visible Prostate Cancer in Active Surveillance: AÂPreliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	1.0	50
172	Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.. Journal of Clinical Oncology, 2015, 33, 5059-5059.	1.6	2
173	Recalibrationâ€...ofâ€...genomicâ€...riskâ€...predictionâ€...modelsâ€...inâ€...prostateâ€...cancerâ€...toâ€...improveâ€...individual-levelâ Journal of Clinical Oncology, 2015, 33, e16122-e16122.	1.6	1
174	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. Urology, 2014, 84, 1434-1441.	1.0	56
175	Editorial Comment. Urology, 2014, 84, 1261-1262.	1.0	0
176	Pathological Examination of Radical Prostatectomy Specimens in Men with Very Low Risk Disease at Biopsy Reveals Distinct Zonal Distribution of Cancer in Black American Men. Journal of Urology, 2014, 191, 60-67.	0.4	127
177	Prostate Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 686-718.	4.9	294
178	Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification.. Journal of Clinical Oncology, 2014, 32, 91-91.	1.6	0
179	An expression-guided screen for small molecules targeting aggressive prostate cancer.. Journal of Clinical Oncology, 2014, 32, e16081-e16081.	1.6	0
180	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 5036-5036.	1.6	0

#	Article	IF	Citations
181	Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 52-52.	1.6	0
182	The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5089-5089.	1.6	0
183	Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.. Journal of Clinical Oncology, 2013, 31, 5033-5033.	1.6	1
184	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomeraseâ€inhibiting therapy. BJU International, 2010, 106, 62-65.	2.5	46
185	Prostate Specific Antigen Testing Among the Elderlyâ€"When To Stop?. Journal of Urology, 2009, 181, 1606-1614.	0.4	63
186	Cystoscopic Management of an Extruded Coil from Arteriovenous Fistula Embolization Using Arthroscopic Instruments. Journal of Endourology, 2008, 22, 1527-1530.	2.1	0
187	Duplex ultrasonography detects clinically significant anomalies of penile arterial vasculature affecting surgical approach to penile straightening. Urology, 2006, 67, 166-169.	1.0	17
188	Prophylactic use of antimicrobials in commonly performed outpatient urologic procedures. Nature Reviews Urology, 2006, 3, 24-31.	1.4	11
189	ADRENAL MYELOLIPOMA. Journal of Urology, 2005, 173, 1760-1760.	0.4	7
190	AMYLOIDOSIS OF THE SEMINAL VESICLE AND HEMATOSPERMIA. Journal of Urology, 2004, 171, 2382-2382.	0.4	8
191	Inguinal bladder hernia. Urology, 2003, 62, 940.	1.0	12